Povidone-iodine used as an adjunct to non-surgical treatment of furcation involvements.
BACKGROUND
The aim of this clinical trial was to evaluate the effect of topically applied povidone-iodine (polyvinylpyrrolidone and iodine [PVP-I]) used as an adjunct to non-surgical therapy of furcation involvements.


METHODS
Forty-four patients presenting at least one Class II furcation involvement that bled on probing with probing depth (PD)>or=5 mm were recruited. Patients were stratified into two treatment groups: 1) subgingival instrumentation by an ultrasonic device using PVP-I (10%) as the cooling liquid (test); and 2) identical treatment using distilled water as the cooling liquid (control). The following clinical outcomes were evaluated: plaque index, bleeding on probing (BOP), position of the gingival margin, relative attachment level (RAL), PD, and relative horizontal attachment level (RHAL). The N-benzoyl-L-arginine-p-nitroanilide (BAPNA) test was used to analyze the trypsin-like activity in dental biofilm. The clinical and biochemical parameters were evaluated at baseline and 1, 3, and 6 months after therapy.


RESULTS
Both groups had similar means of PD reduction and RAL and RHAL gain. At 6 months, these variables were, respectively, 2.31, 1.17, and 1.00 mm in the control group and 2.31, 1.23, and 1.02 mm in the test group. There was also no difference between groups regarding the number of furcation sites presenting RAL gain>or=2 mm. The results of the BAPNA test failed to demonstrate significant differences between groups.


CONCLUSIONS
Non-surgical therapy can effectively treat Class II furcation involvements, and the use of topically applied PVP-I as an adjunct to subgingival instrumentation does not provide additional benefits.
Del Peloso Ribeiro
Erica
E
Department of Prosthodontics and Periodontics, Division of Periodontics, School of Dentistry at Piracicaba, University of Campinas, São Paulo, Brazil.
Bittencourt
Sandro
S
Ambrosano
Glaucia Maria Bovi
GM
Nociti
Francisco H
FH
Sallum
Enilson A
EA
Sallum
Antônio W
AW
Casati
Márcio Zaffalon
MZ
D000287:Administration, Topical; D000328:Adult; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use*; D001586:Benzoylarginine Nitroanilide; D018441:Biofilms; D002863:Chromogenic Compounds; D003774:Dental Plaque Index; D005260:Female; D005500:Follow-Up Studies; D017823:Furcation Defects / Q000188:drug therapy / Q000628:therapy*; D005884:Gingival Hemorrhage / Q000628:therapy; D005889:Gingival Recession / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000188:drug therapy / Q000628:therapy; D010514:Periodontal Pocket / Q000628:therapy; D011206:Povidone-Iodine / Q000008:administration & dosage / Q000627:therapeutic use*; D016037:Single-Blind Method; D013357:Subgingival Curettage; D016896:Treatment Outcome; D014464:Ultrasonic Therapy
D000891:Anti-Infective Agents, Local; D002863:Chromogenic Compounds; D011206:Povidone-Iodine; D001586:Benzoylarginine Nitroanilide